Analysis of the U.S. Cancer Biomarker Testing Market

• Publication date: June 2012
• Report size: 105 pages

This research service analyzes the U.S. cancer biomarker testing market from 2009 to 2017. Topics include an overview of the market, along with definitions, metrics, drivers, and restraints. Also offered is an evaluation of ongoing technology trends and major market competitors and their corresponding market shares and product offerings. Based on this analysis, revenue forecasts and growth rates are projected for each segment of the market. This ...

This research service analyzes the U.S. cancer biomarker testing market from 2009 to 2017. Topics include an overview of the market, along with definitions, metrics, drivers, and restraints. Also offered is an evaluation of ongoing technology trends and major market competitors and their corresponding market shares and product offerings. Based on this analysis, revenue forecasts and growth rates are projected for each segment of the market. This study also provides cancer epidemiology trends, voice-of-customer research on oncologists, and the challenges and strategies for cancer biomarker validation.

Executive Summary
•The United States cancer biomarker testing market generated $x.xx billion in 2011 and is projected to reach $xx.xx billion by 2017 with a CAGR ofx.x5 percent.
•The molecular cancer testing market segment includes mutational and sequencing analysis and it is expected to grow at an average of xx.x percent from 2011 to 2017. This segment was x.x percent of total market revenue in 2011 and is expected to be x.x percent by 2017.
•Important market opportunities that are predicted with high certainty include clinical integration of clinical sequencing technologies and active participation in strategic partnerships. Epigenetic markers, microRNA, and circulating tumor cells are still being clinically validated.
•The falling cost of targeted next-generation sequencing will be extremely cost competitive with the current single-mutation tests. Additional advantages ensure that clinical sequencing will play a role in the future of cancer patient management.
•The primary market restraint is the bottleneck in successful translation of biomarker discoveries into useful clinical tests.
•When making coverage decisions for new tests, private and government health plans want to see evidence of clinical utility and understand the impact of the tests on patient health outcomes as compared to the best alternative.
•The market will continue to consolidate as participants fill in the gaps in their technology set, skill set, or expertise through acquisitions of specialized laboratories.
•Cancer laboratories that are a component of a larger company focused on total cancer patient management, which includes laboratory, imaging, and patient data management services, to provide a stronger value proposition for this dynamic market.
•Voice-of-customer research on oncologists determined that clinical data, test sensitivity, test reimbursement, FDA approval, journal publications, and other endorsements are important for successful test adoption.
•Future cancer biomarker tests will be multiplexed and consist of multiple biomarker types. Key-opinion-leaders (KOLs) predict that the future pathology report will integrate a combination of pathologic and genomic information.

Genomics Industry in the United States

TABLE OF CONTENTS

Executive Summary 4
Market Overview 10
Total U.S. Cancer Biomarker Testing Market —
Industry Trends 15
External Challenges: Drivers and Restraints 28
Forecasts and Trends 40
Market Share and Competitive Analysis 46
Product Analysis 56
Epidemiology 60
Voice-of-Customer Research 73
Cancer Biomarker Validation Challenges and Strategies 77
Molecular Cancer Biomarker Testing Segment Breakdown 80
Traditional Cancer Biomarker Testing Segment Breakdown 84
The Last Word (Conclusions and Implications) 88
Appendix 94